Conference Correspondent
Anticancer drugs should be priced based on the value they deliver to patients, according to Peter B. Bach, MD, Physician, Epidemiologist, Researcher, and Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York. Read More ›
In the long-term, phase 1b/2 PCYC-1102 clinical trial, single-agent ibrutinib, the first FDA-approved once-daily Bruton’s tyrosine kinase inhibitor, showed efficacy and good tolerability in patients with chronic lymphocytic leukemia (CLL) or with small lymphocytic lymphoma (SLL), including patients with deletion (del)17p. Read More ›
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) occur mainly in older patients, who are likely to have several comorbidities and who often are unable to receive aggressive drug therapies, such as alkylating drugs, which are typically used for patients with CLL or SLL. Read More ›
Elderly patients with chronic lymphocytic leukemia (CLL) and younger patients with comorbidities often receive treatment with chlorambucil despite the relative low response rates. Read More ›
In 2016, approximately 18,960 Americans were estimated to be diagnosed with chronic lymphocytic leukemia (CLL), and 4660 were estimated to die from the disease. Read More ›
It is estimated that 18,960 new cases of chronic lymphocytic leukemia (CLL) were diagnosed in 2016, and 4660 deaths. Read More ›
Inpatient chemotherapy is often considered a financial loss, and according to Ali McBride, PharmD, MS, BCPS, BCOP, Clinical Coordinator, Hematology/Oncology, The University of Arizona Cancer Center, Tucson, transitioning chemotherapy to the outpatient setting can be beneficial to patients and providers. Read More ›
Targeted therapy in the management of non–small-cell lung cancer is discussed. Read More ›
Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL. Read More ›
An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented. Read More ›